Health committee  Absolutely. We've been engaged, as has been mentioned, over the timeline. The vaccine task force did select six companies to be supported by NRC IRAP. Entos Pharmaceuticals was one of those companies. We have been working closely with some fantastic people at NRC to help us with

Health committee  Absolutely, hindsight is 20/20, but I think it's extremely clear that, if you look at success around the globe, decisive and upfront funding of multiple vaccine candidates all the way through to the end was key to both their success and their speed. We talked a lot about being

Health committee  Obviously we've been busy developing a vaccine and getting our manufacturing up to speed, but absolutely, we've exhausted pretty much every connection that we had to try to reach members of the government, including a letter directly to the Prime Minister's Office.

Health committee  I'd love to put that in perspective. It's estimated at between $350 million to $600 million to bring a vaccine all the way from discovery to the end of phase three and licensure. A small smattering of this funding was offered to companies throughout Canada—through the NRC, for in

Health committee  I can't answer, as I'm not a vaccine procurement specialist, but I would say it's more a question of logistics. Expecting other countries to develop and manufacture vaccines and not prioritize their own population over other countries was a little misguided.

Health committee  Thank you, Chair. Good morning, ladies and gentlemen. I appreciate the opportunity to share our perspective today. My name is John Lewis. I'm the founder and CEO of a Canadian company called Entos Pharmaceuticals. It's located in Edmonton, Alberta. I'm also a professor at the fa